Masimo CORP DEF 14A proxy statements

Masimo Corporation's proxy statement reveals a year of significant changes, including a CEO transition, board realignment, and strategic initiatives focused on long-term growth and shareholder value.

Masimo is challenging the influence of proxy advisory firms ISS and Glass Lewis as Politan Capital Management seeks additional board seats.

Masimo Corporation updates stockholders on the 2024 Annual Meeting, addressing potential uncertainties related to Politan Capital Management's director nominations.

Masimo updates its website with a testimonial from a St. Luke's University Health Network executive, emphasizing the positive impact of Masimo's Patient SafetyNet on patient outcomes and quality data.

A high-stakes proxy battle at Masimo, pitting founder Joe Kiani against activist investor Quentin Koffey, culminates in a shareholder vote that could determine the company's future leadership and direction.

Masimo updates its website with letters of support for its CEO, Joe Kiani, as it faces a proxy battle ahead of the 2024 Annual Meeting of Stockholders.

Masimo collaborates with Qualcomm and Google to create reference platforms for Wear OS smartwatches, aiming to streamline OEM development and enhance device performance with advanced biosensing technology.

Masimo's CEO, Joe Kiani, discusses the company's legal battle with Apple, its partnership with Google, and the ongoing proxy fight with Politan Capital Management.

Masimo is engaged in a proxy battle with Politan Capital, marked by court rulings against Politan for false statements and contempt, as the company urges stockholders to vote for its director nominees.

Masimo updates its website to advocate for its current leadership and highlight its achievements amidst a proxy battle with Politan Capital Management.

Proxy advisory firm Egan-Jones recommends Masimo stockholders vote for director nominees Joe Kiani and Christopher Chavez, citing Kiani's critical role in innovation and potential disruption from a Politan win.

Masimo claims Politan Capital Management and Quentin Koffey made false and misleading statements to stockholders regarding key issues like the spin-off, board's role in the sale process, and the outcome of the sale process.

Masimo is urging stockholders to vote for its director nominees, Joe Kiani and Christopher Chavez, at the upcoming Annual Meeting on September 19, 2024, emphasizing the importance of their vote in determining the company's future and investment value.

Masimo refutes claims by Politan Capital Management regarding shared non-public information and alleged empty voting schemes as the proxy battle intensifies.

Masimo Corporation has filed an amended revised proxy statement and urges stockholders to resubmit their votes for the 2024 Annual Meeting.

Masimo is exploring options for its consumer business, including a joint venture or sale, while focusing on healthcare growth driven by strong census and contracting, all amidst a proxy battle with Politan Capital.

Masimo Corporation encourages stockholders to read the amended revised proxy statement for the 2024 Annual Meeting, emphasizing the importance of resubmitting votes due to revisions.

Masimo Corporation is urging its stockholders to resubmit their votes for the 2024 Annual Meeting following revisions to its proxy statement, amidst a challenge from Politan Capital Management LP.

Masimo is urging stockholders to vote for its director nominees, Joe Kiani and Christopher Chavez, citing concerns over Politan's intentions and Quentin Koffey's actions.

Masimo Corporation updates its website, www.ProtectMasimosFuture.com, in preparation for the 2024 Annual Meeting of Stockholders, amidst ongoing litigation with Politan Capital Management LP.

Masimo Corporation updates its website with materials related to the upcoming 2024 Annual Meeting of Stockholders, addressing forward-looking statements and ongoing discussions regarding its consumer business separation.

Masimo is urging stockholders to vote for its director nominees, Joe Kiani and Christopher Chavez, to protect the company's future and investment value amidst a proxy battle with Politan Capital Management.

Masimo is engaged in a proxy contest while evaluating the separation of its consumer business to unlock stockholder value.

Masimo files revised proxy materials and urges stockholders to vote for its director nominees, highlighting strong Q2 results and a strategy for long-term, sustainable growth amidst a proxy battle with Politan.

Masimo is urging stockholders to reject Politan's nominees at the upcoming annual meeting, citing concerns over the activist investor's potential influence on the company's innovation and strategic direction.

Masimo Corporation updates its website with materials related to the upcoming 2024 Annual Meeting of Stockholders, including letters from medical professionals, amidst an ongoing proxy battle with Politan Capital Management.

Masimo CEO Joe Kiani addresses shareholders, defending the company's performance and strategy against criticism from activist investor Quentin Koffey, while highlighting a lawsuit to correct alleged misstatements.

Masimo Corporation has postponed its 2024 Annual Meeting of Stockholders to September 19, 2024, and initiated litigation against Politan Capital Management LP for alleged material misstatements and omissions in their proxy materials.

Masimo refutes Politan Capital's claims, asserting strong healthcare business performance and a credible plan for future growth, while urging shareholders to vote for Masimo's nominees.

Masimo publicly criticizes Politan Capital and Quentin Koffey for actions allegedly contradicting their stated commitment to good governance, urging stockholders to vote for Masimo's nominees.